Physician profile
Le Yu
NPI 1801080320
$1,054.85
in general payments reported to CMS, 2019-2025
13 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2021: $52.74 · 2022: $108 · 2023: $114 · 2024: $143 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $374.09 | 2019-2025 | Clareon, Tryptyr, Eysuvis |
| Johnson & Johnson Surgical Vision, INC. | $140.56 | 2019 | |
| Abbvie INC. | $102.26 | 2025 | |
| Glaukos Corporation | $99.04 | 2019-2024 | Idose |
| Sun Pharmaceutical Industries INC. | $69.72 | 2023 | Cequa |
| Amgen INC. | $48.11 | 2025 | Tepezza |
| Allergan, INC. | $40.21 | 2021 | |
| Abiomed | $39.15 | 2019 | |
| Bausch & Lomb Americas INC. | $38.23 | 2022-2024 | Stellaris |
| Oyster Point Pharma, INC. | $36.89 | 2024-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $34.02 | 2025 | Xdemvy |
| Rxsight INC | $20.04 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Ocular Therapeutix, INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Le Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.